FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms

The continuing heavy toll of the COVID-19 pandemic necessitates development of therapeutic options. We adopted structure-based drug repurposing to screen FDA-approved drugs for inhibitory effects against main protease enzyme (Mpro) substrate-binding pocket of SARS-CoV-2 for non-covalent and covalent...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biomedicine & pharmacotherapy 2023-06, Vol.162, p.114614-114614, Article 114614
Hauptverfasser:	Ahmed, Mahmoud S., Farag, Ayman B., Boys, Ian N., Wang, Ping, Menendez-Montes, Ivan, Nguyen, Ngoc Uyen Nhi, Eitson, Jennifer L., Ohlson, Maikke B., Fan, Wenchun, McDougal, Matthew B., Mar, Katrina, Thet, Suwannee, Ortiz, Francisco, Kim, Soo Young, Solmonson, Ashley, Williams, Noelle S., Lemoff, Andrew, DeBerardinis, Ralph J., Schoggins, John W., Sadek, Hesham A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - pharmacology Atovaquone - pharmacology COVID-19 Dihydroorotate Dehydrogenase Dronedarone - pharmacology Drug Repositioning Humans Mebendazole - pharmacology Molecular Docking Simulation Molecular Dynamics Simulation Pandemics Protease Inhibitors - pharmacology Purine Metabolism Purines - pharmacology SARS-CoV-2 Structure-based drug repurposing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!